Advertisement

Topics

FDA gives Zelboraf priority review as potential first ever therapy for rare blood disease

07:19 EDT 8 Aug 2017 | thePharmaLetter

Roche subsidiary Genentech has received priority review status for its bid to broaden the label for Zelboraf…

Original Article: FDA gives Zelboraf priority review as potential first ever therapy for rare blood disease

NEXT ARTICLE

More From BioPortfolio on "FDA gives Zelboraf priority review as potential first ever therapy for rare blood disease"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...